Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Is Plunging Today

By Prosper Junior Bakiny – Aug 7, 2020 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not pleased with the company’s second-quarter financial results.

What happened? 

Healthcare giant Illumina (ILMN 6.56%) reported its second-quarter financial results after the market closed on Thursday. The company's update showed that its performance during the period came short of expectations. As a result, investors are selling off shares of Illumina today, and its stock is down by 13.1% as of 12:51 p.m. EDT.

So what

During the second quarter, Illumina recorded revenue of $633 million -- a 25% year-over-year decrease -- which is what analysts were expecting on average. Also, the company recorded a non-GAAP (adjusted) net income of $92 million, or $0.62 on a per-share basis. During the prior-year quarter, Illumina had recorded a non-GAAP net income of $200 million and earnings per share (EPS) of $1.35. Note that, on average, analysts were expecting the company's non-GAAP EPS to come in at $0.67.

Francis deSouza, CEO of Illumina, said, "As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers' operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale."

Man standing on a downward-pointing graph

Image source: Getty Images.

Now what

The COVID-19 pandemic will continue to present serious obstacles to Illumina. However, the genome sequencing market is ripe for growth, and Illumina is one of the leaders in this market. The healthcare company is poised to rebound once the crisis subsides, which means now may be a good opportunity to purchase its shares. After today's losses on the market, Illumina's stock is up by 4.4% year to date, which is more or less in line with the performance of the S&P 500 since the year began. For investors who opt to initiate a position in Illumina today, patience will be rewarded down the road. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina Stock Quote
Illumina
ILMN
$218.52 (6.56%) $13.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.